ESC/ERS low-risk profile achievement accurately predicts mortality in scleroderma-associated PAH
Conclusions: Our findings suggest that an abbreviated version of guidelines’ risk assessment accurately predicts SScPAH mortality. Achievement of low-risk profile is associated with better outcome and could represent a valid surrogate endpoint for clinical trials in SScPAH.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Mercurio, V., Diab, N., Peloquin, G., Housten-Harris, T., Damico, R., Kolb, T., Mathai, S., Hassoun, P. Tags: Pulmonary hypertension Source Type: research
More News: Clinical Trials | Hypertension | Pulmonary Hypertension | Respiratory Medicine | Scleroderma